
Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
VJHemOnc Podcast
FDA Approval of Luspattersept for Frontline Therapy in Lower-Risk MDS
Discussion on the FDA approval of Luspattersept for frontline therapy in lower-risk MDS, comparing it to erythropoietin (EPO) and exploring the factors that influence treatment choice. The chapter also highlights the goal of treating cytopenias and anemia to improve patient outcomes and quality of life.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.